Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: Inhibition of TGFβ improves hematopoietic stem cell niche and ameliorates cancer-related anemia

Fig. 6

Inhibition of the TGFβ pathway rescues the HSC niche deterioration. a Western blotting analysis of phosphorylated Smad2/3 and total Smad2/3 proteins in the bone marrow of control, LLC, and LLC+SB505124 mice. b mRNA expression of Acta2 in the bone marrow of control, LLC, and LLC+SB505124 mice. c Representative confocal images show the expression of α-SMA protein in the trabecular bone of control, LLC, and LLC+SB505124 mice. Scale bar, 100 μm. d mRNA expression of the fibrotic factors, Col3a1 and Fn, in the bone marrow of control, LLC, and LLC+SB505124 mice. e, f CFU-F assays and quantification from the bone marrow of control, LLC, and LLC+SB505124 mice. Representative images of CFU-Fs stained with crystal violet. g, h qPCR detection of osteoblastic genes and adipogenic markers in differentiated MSC. i The mRNA expression of the hematopoietic factors, Cxcl12 and KitL, in the bone marrow of control, LLC, and LLC+SB505124 mice. j During CRA, the osteoclastic process released excessive TGFβ and activated the TGFβ pathway in the bone marrow, which induced a deterioration of the HSC niche and the blockage of hematopoiesis. By inhibiting the TGFβ signaling pathway with SB505124, the HSC niche and hematopoiesis were restored, and the CRA symptoms also showed relieved. *P < 0.05, **P < 0.01, ***P < 0.001; assessed by Student’s t test

Back to article page